Physician profile
William T Bates
NPI 1073552121
$10,814.49
in general payments reported to CMS, 2019-2025
54 companies · $2,306 in 2025
The $2,306 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $742 · 2021: $1,152 · 2022: $1,586 · 2023: $1,965 · 2024: $1,790 · 2025: $2,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,036 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,036.44 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,112.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,472.64 | 2019-2025 | |
| Abbvie INC. | $586.88 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $583.94 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $536.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $523.51 | 2019-2025 | Spravato |
| Abbott Laboratories | $383.95 | 2020-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $382.95 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $378.68 | 2019-2025 | Shingrix, Arexvy, Boostrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.53 | 2019-2025 | Jardiance |
| Amgen INC. | $354.65 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $323.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Braeburn INC. | $305.40 | 2023-2024 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.27 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $160.15 | 2020-2021 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $150.42 | 2019-2025 | Mounjaro, Kisunla |
| Takeda Pharmaceuticals U.S.A., INC. | $144.39 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.05 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $118.35 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Merck Sharp & Dohme LLC | $115.22 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $114.70 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $106.53 | 2022-2025 | Camzyos, Eliquis |
| Corcept Therapeutics | $104.36 | 2023-2025 | Korlym |
| Boston Scientific Corporation | $96.86 | 2025 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company Ltd. | $91.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $86.86 | 2019-2021 | |
| Inspire Medical Systems, INC. | $65.09 | 2023-2025 | Inspire |
| Esperion Therapeutics, INC. | $64.90 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $60.96 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $45.52 | 2023-2024 | Voquezna |
| Optinose US, INC. | $44.95 | 2024 | |
| Exact Sciences Corporation | $43.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $42.84 | 2024 | Rexulti |
| Dexcom, INC. | $34.48 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $31.02 | 2023 | Krystexxa |
| Eisai INC. | $27.36 | 2020-2021 | |
| Allergan, INC. | $26.19 | 2020 | |
| Biogen, INC. | $25.93 | 2025 | Skyclarys |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Jazz Pharmaceuticals INC. | $24.03 | 2022 | |
| Verona Pharma, INC. | $23.85 | 2025 | Ohtuvayre |
| Seqirus USA INC | $22.20 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Sumitomo Pharma America, INC. | $21.16 | 2025 | Gemtesa |
| Irhythm Technologies, INC. | $20.48 | 2024 | Zio Xt Patch, Zio Monitor |
| Insulet Corporation | $19.82 | 2024 | Omnipod |
| Evoke Pharma, INC. | $19.29 | 2022 | |
| Upsher-Smith Laboratories LLC | $18.93 | 2021 | |
| Alkermes, INC. | $18.75 | 2019 | |
| Viatris Specialty LLC | $15.15 | 2025 | Yupelri |
| Saluda Medical Americas, INC. | $14.69 | 2025 | Evoke |
| Paratek Pharmaceuticals, INC. | $13.11 | 2023 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $11.91 | 2020 | |
| Genentech USA, INC. | $11.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.